Abstract：Objective To explore the expression of AHNAK2 in lung adenocarcinoma and to construct a nomogram to predict the survival of lung adenocarcinoma patients based on AHNAK2.Methods The expression of AHNAK2 in tumor tissues and normal tissues was analyzed based on the TCGA database and the CPTAC database. The influence of AHNAK2 expression on the prognosis of patients was studied by drawing the survival curve of AHNAK2, and the variables were screened by COX multivariate analysis and included in the nomogram model to predict the prognosis and survival of patients.Results The mRNA and protein levels of AH- NAK2 in tumor tissues were significantly higher than those in normal tissues. Survival curve analysis showed that patients with high AHNAK2 expression had a shorter overall survival time and a shorter time to the first progression of the disease than those in the low expression group. The results of COX multivariate analysis showed that the high expression of AHNAK2, T stage, N stage, TNM stage, and radiotherapy were all independent risk factors affecting the survival of patients (P<0.05).The nomogram model had good stability and accuracy. The area under the ROC curve of the model predicting 1-year, 3-year, and 5-year survival probability was 0.69, 0.76, and 0.71, respectively, and the KM survival curve of the model score suggested that the high group had a shorter survival time than the low group.Conclusions The mRNA and protein expressions of AHNAK2 in lung adenocarcinoma tissues are significantly higher than those in normal tissues, and patients with high AHNAK2 expression have poor prognosis. The nomogram model based on AHNAK2 has good stability and accuracy.
范静, 赵海滨. 基于AHNAK2构建预测肺腺癌患者生存的列线图模型[J]. 武警医学, 2023, 34(8): 682-687.
FAN Jing, ZHAO Haibin. Construction of a nomogram model for predicting survival of patients with lung adenocarcinoma based on AHNAK2. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(8): 682-687.
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249.
[2]
Sher T, Dy G K, Adjei A A. Small cell lung cancer[J]. Mayo Clin Proc, 2008,83(3):355-367.
[3]
Zappa C, Mousa S A. Non-small cell lung cancer: Current treatment and future advances[J]. Transl Lung Cancer Res, 2016,5(3):288-300.
[4]
Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019,69(1):7-34.
[5]
Koguchi D, Matsumoto K, Shimizu Y, et al. Prognostic impact of ahnak2 expression in patients treated with radical cystectomy[J]. Cancers (Basel), 2021,13(8).
[6]
Yang Z Q, Liu Y J, Zhou X L. An integrated microarray analysis reveals significant diagnostic and prognostic biomarkers in pancreatic cancer[J]. Med Sci Monit, 2020,26:e921769.
[7]
Ye R, Liu D, Guan H, et al. Ahnak2 promotes thyroid carcinoma progression by activating the nf-κb pathway[J]. Life Sci, 2021,286:120032.
[8]
Komuro A, Masuda Y, Kobayashi K, et al. The ahnaks are a class of giant propeller-like proteins that associate with calcium channel proteins of cardiomyocytes and other cells[J]. Proc Natl Acad Sci U S A, 2004,101(12):4053-4058.
[9]
Bhasin M K, Ndebele K, Bucur O, et al. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier[J]. Oncotarget, 2016,7(17):23263-23281.
[10]
Wang M, Li X, Zhang J, et al. Ahnak2 is a novel prognostic marker and oncogenic protein for clear cell renal cell carcinoma[J]. Theranostics, 2017,7(5):1100-1113.
[11]
Mehlen P, Puisieux A. Metastasis: A question of life or death[J]. Nat Rev Cancer, 2006,6(6):449-458.
[12]
Chaffer C L, San Juan B P, Lim E, et al. Emt, cell plasticity and metastasis[J]. Cancer Metastasis Rev, 2016,35(4):645-654.
[13]
Zhitnyak I Y, Rubtsova S N, Litovka N I, et al. Early events in actin cytoskeleton dynamics and e-cadherin-mediated cell-cell adhesion during epithelial-mesenchymal transition[J]. Cells, 2020,9(3):179-188.
[14]
Canel M, Serrels A, Frame M C, et al. E-cadherin-integrin crosstalk in cancer invasion and metastasis[J]. J Cell Sci, 2013,126(2):393-401.
[15]
Han H, Kursula P.Periaxin and ahnak nucleoprotein 2 form intertwined homodimers through domain swapping[J]. J Biol Chem, 2014,289(20):14121-14131.
[16]
Kirov A, Kacer D, Conley BA, et al. Ahnak2 participates in the stress-induced nonclassical fgf1 secretion pathway[J]. J Cell Biochem, 2015,116(8):1522-1531.
[17]
Li M, Liu Y, Meng Y, et al. Ahnak nucleoprotein 2 performs a promoting role in the proliferation and migration of uveal melanoma cells[J]. Cancer Biother Radiopharm, 2019,34(10):626-633.
[18]
Liu G, Guo Z, Zhang Q, et al. Ahnak2 promotes migration, invasion, and epithelial-mesenchymal transition in lung adenocarcinoma cells via the tgf-β/smad3 pathway[J]. Onco Targets Ther, 2020,13:12893-12903.
[19]
Lu D, Wang J, Shi X, et al. Ahnak2 is a potential prognostic biomarker in patients with pdac[J]. Oncotarget, 2017,8(19):31775-31784.
[20]
Zhou Y Y, Kang Y T, Chen C, et al. Combination of tnm staging and pathway based risk score models in patients with gastric cancer[J]. J Cell Biochem, 2018,119(4):3608-3617.
[21]
Iasonos A, Schrag D, Raj G V, et al. How to build and interpret a nomogram for cancer prognosis[J]. J Clin Oncol, 2008,26(8):1364-1370.
2023, Vol. 34 
